Abstract
e15203 Background: The tumors of the biliary tract can arise anywhere in the tree biliary or less frequent from transdifferentiation of hepatocytes. This tumor is lethal with heterogeneous behavior and complex molecular biology representing 0.6-1% of tumors among adults. Several studies highlight the role of HER2 in cholangiocarcinoma pathogenesis and its expression seems to be present from the onset of carcinogenesis. The prognostic value of HER2 in this population is matter of debate and the pattern of expression of HER2 is heterogeneous as in gastric cancer. The aim of this study was to evaluate the prognostic role of HER2 by immunohistochemistry using the methodology validated for gastric cancer in western population with cholangiocarcinoma. Methods: We have done a retrospective review of clinical and pathological features on eletronic medical charts of patients with cholangiocarcinoma and HER2 immunohistochemistry testing using gastric cancer methodology. Results: Among the 46 patients evaluated, 38 were evaluated for the expression of HER2. The expression of Her (2 or 3+) was found in (30%). In multivariate analysis, the expression of HER2 (2 or 3 +) was a independent prognostic factor with HR for mortality of 3.08 (1.23 to 7.28) with p: 0.01. This prognostic factor was observed in both localized and metastatic disease. Conclusions: HER2 immunohistochemistry using gastric cancer methodology was positive (2 or 3+) in 30% of our western population of cholangiocarcinoma and was a independent prognostic factor. Prospective studies are needed to validate the best method for assessing HER2 expression and if there is a predictive value for using anti-HER therapy in this selected population.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call